%0 Clinical Trial
%T Risk of newly detected infections and cervical abnormalities in women seropositive for naturally acquired human papillomavirus type 16/18 antibodies: analysis of the control arm of PATRICIA.
%A Castellsagué X
%A Naud P
%A Chow SN
%A Wheeler CM
%A Germar MJ
%A Lehtinen M
%A Paavonen J
%A Jaisamrarn U
%A Garland SM
%A Salmerón J
%A Apter D
%A Kitchener H
%A Teixeira JC
%A Skinner SR
%A Limson G
%A Szarewski A
%A Romanowski B
%A Aoki FY
%A Schwarz TF
%A Poppe WA
%A Bosch FX
%A de Carvalho NS
%A Peters K
%A Tjalma WA
%A Safaeian M
%A Raillard A
%A Descamps D
%A Struyf F
%A Dubin G
%A Rosillon D
%A Baril L
%J J Infect Dis
%V 210
%N 4
%D Aug 2014 15
%M 24610876
%F 7.759
%R 10.1093/infdis/jiu139
%X <B>BACKGROUND: </B>We examined risk of newly detected human papillomavirus (HPV) infection and cervical abnormalities in relation to HPV type 16/18 antibody levels at enrollment in PATRICIA (Papilloma Trial Against Cancer in Young Adults; NCT00122681).<BR><B>METHODS: </B>Using Poisson regression, we compared risk of newly detected infection and cervical abnormalities associated with HPV-16/18 between seronegative vs seropositive women (15-25 years) in the control arm (DNA negative at baseline for the corresponding HPV type [HPV-16: n = 8193; HPV-18: n = 8463]).<BR><B>RESULTS: </B>High titers of naturally acquired HPV-16 antibodies and/or linear trend for increasing antibody levels were significantly associated with lower risk of incident and persistent infection, atypical squamous cells of undetermined significance or greater (ASCUS+), and cervical intraepithelial neoplasia grades 1/2 or greater (CIN1+, CIN2+). For HPV-18, although seropositivity was associated with lower risk of ASCUS+ and CIN1+, no association between naturally acquired antibodies and infection was demonstrated. Naturally acquired HPV-16 antibody levels of 371 (95% confidence interval [CI], 242-794), 204 (95% CI, 129-480), and 480 (95% CI, 250-5756) EU/mL were associated with 90% reduction of incident infection, 6-month persistent infection, and ASCUS+, respectively.<BR><B>CONCLUSIONS: </B>Naturally acquired antibodies to HPV-16, and to a lesser extent HPV-18, are associated with some reduced risk of subsequent infection and cervical abnormalities associated with the same HPV type.